Progress in the Treatment of Primary Biliary Cholangitis

Authors

  • Caixia Zhao School of Public Health, North China University of Science and Technology, Tangshan 063200, China

Keywords:

Primary biliary cholangitis, Treatment, Ursodeoxycholic acid, Obeticolic acid, Betrate drugs

Abstract

Primary biliary cholangitis (PBC) is a chronic, progressive, and rare autoimmune inflammatory disease of the interlobular bile duct, leading to bile stasis and secondary damage to liver cells. Ursodeoxycholic acid (UDCA) is currently the only drug approved for the treatment of PBC, but about 40% of patients still have poor response to UDCA treatment. Based on this situation, research on the treatment of PBC has been continuously deepened in recent years. This article reviews the progress of PBC treatment.

Downloads

Published

2022-12-30

How to Cite

Zhao, C. (2022). Progress in the Treatment of Primary Biliary Cholangitis. International Journal of Advance in Clinical Science Research, 1, 17–19. Retrieved from https://h-tsp.com/index.php/ijacsr/article/view/55

Issue

Vol. 1 (2022)

Section

Articles